Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study

International Journal of Urology

Volumn 14, Issue 4, 2007, Pages 317-320

  Rodrigues, Paulo ^a,b   Hering, Flavio O ^a   Bruna, Paulo ^a   Meller, Alex ^a   Afonso, Yuri ^a  

^a HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Androgen deprivation therapy (ADT); Clodronate; Hormone therapy; Osteoporosis; Prostate cancer; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GONADORELIN AGONIST; ZOLEDRONIC ACID;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BONE DENSITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL ANALYSIS;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DIPHOSPHONATES; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORCHIECTOMY; OSTEOPOROSIS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 34247591086     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01721.x     Document Type: Article

References (24)

1. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 2003 97 (3 Suppl. 789 92.
2. Groot MT, Kruger CGCB, Pelger RCM, Uyl-de Groot CA. Financial cost of patients with prostate cancer osseous metastasis in the Netherlands. Eur. Urol. 2003 43 : 226 30.
3. Berruti A, Dogliotti R, Bitossi R, Fasolis G, Gorzegno G, Bellina M. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease. predictive role of bone resorption and formation markers evaluated at baseline. J. Urol. 2000 164 : 1248 51.
4. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 2002 94 : 1458 62.
5. Verreuther R. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A Pilot Study on Clodronate. Br. J. Urol. 1993 72 : 792 5.
6. Rodrigues P, Hering F, Campagnari JC. Use of Bisphosphonates can dramatically improve pain in advanced hormone refractory prostate cancer patients. Prostate Cancer Prostatic Dis. 2004 7 : 350 4.
7. Luckman SP, Huges DE, Loxon FF. Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins including ras. J. Bone Miner Res. 1998 13 : 581 4.
8. Adami S, Salvagno G, Guarrera G. Dichloromethylene-bisphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J. Urol. 1985 134 : 1152 5.
9. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos. Int. 2000 11 : 192 6.
10. Eriksson S, Eriksson A, Stege R et al. Bone mineral density in patients with prostate cancer treated with orchiectomy and estrogens. Calcif. Tissue Int. 1995 57 : 97 100.
11. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J. Urol. 2002 167 : 1952 5.
12. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J. Am. Geriatr. Soc. 2003 51 : 364 8.
13. Dickman PW, Adolfsson J, Åström K, Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J. Urol. 2004 172 : 2208 011.
14. Smith MR, McGovern FJ, Falon MA, Schenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 2001 91 : 2238 41.
15. Faulkner KG, Orwoll E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J. Clin. Densitom. 2002 5 : 87 91.
16. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998 280 : 2077 90.
17. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Méd. 2001 345 : 948 52.
18. Jagdev SP, Purohit OP, Heatley S, Herling C, Coleman RE. Comparison of effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption with metastatic bone disease. Ann. Oncol. 2001 12 : 1433 6.
19. Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 2003 20 : 175 8.
20. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 2000 343 : 604 9.
21. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J. Urol. 2003 169 : 2008 12.
22. Daniel HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer : J. Urol. 2000 163 : 181 5.
23. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J. Urol. 1999 161 : 1219 23.
24. Stock JL, Bell NH, Chesnut CH 3rd et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am. J. Med. 2001 103 : 291 5.